Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Αlexandros Briasoulis, Sentiljana Gumeni, Panagiotis Malandrakis, Eleni‐Dimitra Papanagnou, Magdalini Migkou, Nikolaos Kanellias, Efstathios Kastritis, Ioannis P. Trougakos, Meletios Α. Dimopoulos
Topics & Concepts
MedicineMultiple myelomaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakBooster (rocketry)VirologyImmunologyInternal medicineOutbreakAstronomyInfectious disease (medical specialty)PhysicsDiseaseSARS-CoV-2 and COVID-19 ResearchMultiple Myeloma Research and TreatmentsCOVID-19 Clinical Research Studies